Table I.
Patient characteristics
| Case | Sex | Age (y) | Weight (kg) | AD onset | EASI score | Previous treatment (face and neck/other parts) | Eos (/μL) | LDH level (IU/L) | Total IgE level (kU/L) | TARC level (pg/mL) | IL-4 level (pg/mL) | Starting dosage of dupilumab | Onset of DFR (days after starting dupilumab) | Any attempt to treat DFR | Complete resolution of DFR after the onset (d) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 16 | 69.4 | Infancy | 16.1 | TCI /TCS (class Ⅱ) | 360 | 225 | 1530 | 389 | <2 | 600 mg (followed by 300 mg given every other week) | 73 | TCS combined with ketoconazole | 116 |
| 2 | M | 15 | 67.4 | Infancy | 10.5 | TCS (class Ⅱ) /TCS (class Ⅱ) | 230 | 227 | 12900 | 1545 | 7.2 | 600 mg (followed by 300 mg given every other week) | 63 | Instructed to apply adequate TCS and undergo observation | 105 |
| 3 | M | 17 | 45 | Infancy | 25.9 | Delgocitinib/Delgocitinib | NA | NA | NA | NA | NA | 600 mg (followed by 300 mg given every other week) | 16 | Instructed to apply adequate delgocitinib and undergo observation | 98 |
Eos, Eosinophil; LDH, lactate dehydrogenase; M, male; NA, not applicable; TARC, thymus and activation-regulated chemokine.
The blood test results are the most recent values before the start of dupilumab treatment. The case 1 and 2 values were obtained 442 and 261 days before the start of dupilumab therapy, respectively.